| Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes H Masuda, TM Brewer, DD Liu, T Iwamoto, Y Shen, L Hsu, JS Willey, ... Annals of oncology 25 (2), 384-391, 2014 | 134 | 2014 |
| Does optical coherence tomography identify arterial healing after stenting? An in vivo comparison with histology, in a rabbit carotid model F Prati, M Zimarino, E Stabile, G Pizzicannella, T Fouad, R Rabozzi, ... Heart 94 (2), 217-221, 2008 | 122 | 2008 |
| The MD Anderson manual of medical oncology HM Kantarjian, RA Wolff, CA Koller McGraw Hill Professional, 2011 | 107 | 2011 |
| Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system TM Fouad, AMG Barrera, JM Reuben, A Lucci, WA Woodward, ... The Lancet Oncology 18 (4), e228-e232, 2017 | 99 | 2017 |
| Inflammatory breast cancer: what to know about this unique, aggressive breast cancer A Menta, TM Fouad, A Lucci, H Le-Petross, MC Stauder, WA Woodward, ... Surgical Clinics 98 (4), 787-800, 2018 | 96 | 2018 |
| Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis TM Fouad, T Kogawa, DD Liu, Y Shen, H Masuda, R El-Zein, ... Breast cancer research and treatment 152, 407-416, 2015 | 94 | 2015 |
| Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer M Mego, H Gao, EN Cohen, S Anfossi, A Giordano, T Sanda, TM Fouad, ... Journal of Cancer 7 (9), 1095, 2016 | 89 | 2016 |
| Risk factors for inflammatory breast cancer and other invasive breast cancers C Schairer, Y Li, P Frawley, BI Graubard, RD Wellman, DSM Buist, ... Journal of the National Cancer Institute 105 (18), 1373-1384, 2013 | 84 | 2013 |
| The role of inflammation in inflammatory breast cancer TM Fouad, T Kogawa, JM Reuben, NT Ueno Inflammation and cancer, 53-73, 2014 | 80 | 2014 |
| Acute myeloid leukemia developing in patients with autoimmune diseases SM Ramadan, TM Fouad, V Summa, SKH Hasan, F Lo-Coco haematologica 97 (6), 805, 2012 | 77 | 2012 |
| Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab+ chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC JV Heymach, D Harpole, T Mitsudomi, JM Taube, G Galffy, M Hochmair, ... Cancer Research 83 (8_Supplement), CT005-CT005, 2023 | 72 | 2023 |
| Novel therapeutic strategies in the treatment of triple-negative breast cancer K Oualla, HM El-Zawahry, B Arun, JM Reuben, WA Woodward, ... Therapeutic advances in medical oncology 9 (7), 493-511, 2017 | 71 | 2017 |
| Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab+ chemotherapy followed by adjuvant durvalumab for the treatment of … JV Heymach, T Mitsudomi, D Harpole, M Aperghis, S Jones, H Mann, ... Clinical Lung Cancer 23 (3), e247-e251, 2022 | 66 | 2022 |
| Perioperative durvalumab for resectable non–small-cell lung cancer JV Heymach, D Harpole, T Mitsudomi, JM Taube, G Galffy, M Hochmair, ... New England Journal of Medicine 389 (18), 1672-1684, 2023 | 57 | 2023 |
| Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer M Mego, H Gao, EN Cohen, S Anfossi, A Giordano, S Tin, TM Fouad, ... Oncotarget 8 (22), 35656, 2017 | 51 | 2017 |
| Epidemiological risk factors associated with inflammatory breast cancer subtypes RL Atkinson, R El-Zein, V Valero, A Lucci, TB Bevers, T Fouad, W Liao, ... Cancer Causes & Control 27, 359-366, 2016 | 50 | 2016 |
| Circulating tumor cells in newly diagnosed inflammatory breast cancer M Mego, A Giordano, U De Giorgi, H Masuda, L Hsu, M Giuliano, ... Breast Cancer Research 17, 1-12, 2015 | 50 | 2015 |
| MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer L Huo, Y Wang, Y Gong, S Krishnamurthy, J Wang, L Diao, CG Liu, X Liu, ... Modern Pathology 29 (4), 330-346, 2016 | 47 | 2016 |
| Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015 D Zardavas, TM Fouad, M Piccart The Breast, 2015 | 32 | 2015 |
| The ‘indirect costs’ of underfunding foreign partners in global health research: A case study JT Crane, I Andia Biraro, TM Fouad, Y Boum, D R. Bangsberg Global Public Health 13 (10), 1422-1429, 2018 | 28 | 2018 |
Wendy WoodwardProfessor, MD Anderson Cancer CenterVerified email at mdanderson.org
